Trichorrhexis Invaginata (Netherton Syndrome or Bamboo Hair)

Back

Background

Netherton Syndrome is a rare autosomal recessive genodermatosis characterized by congenital ichthyosiform erythroderma, an atopic diathesis, and a characteristic hair-shaft abnormality known as trichorrhexis invaginata. The condition begets the potential for severe complications for the affected individual, especially in the neonatal period. Chronic skin inflammation results in scaling and exfoliation, predisposing these patients to life-threatening infections, sepsis, and dehydration. Skin manifestations and associated symptoms may vary considerably among individuals with Netherton syndrome.

Historical background

In 1937, Touraine and Solente[1] first noted the association between hair-shaft defects (bamboo node) and ichthyosiform erythroderma. Còmel[2] first coined the term ichthyosis linearis circumflexa in 1949, although more than two decades earlier Rille (Fruhwald[3] ) had previously recorded the distinctive features of ichthyosis linearis circumflexa. The condition is occasionally referred to as Còmel-Netherton syndrome.

In 1958, Netherton[4] described a young girl with generalized scaly dermatitis and fragile nodular hair-shaft deformities, which he termed trichorrhexis nodosa. Later, this was more appropriately renamed as trichorrhexis invaginata (bamboo hair) for a ball-and-socket–type hair-shaft deformity at the suggestion of Wilkinson et al.[5]

In 1974, Mevorah et al[6] established the clinical relationship between ichthyosis linearis circumflexa and Netherton syndrome, and an atopic diathesis was found to occur in approximately 75% of patients with Netherton syndrome.

Pathophysiology

The Netherton syndrome (Mendelian Inheritance in Man [MIM] #256500) is inherited as an autosomal recessive disorder due to mutations of both copies of the SPINK5 gene (localized to band 5q31-32).[7] Each SPINK5 mutation leads to a different length of LEKTI protein, resulting in genotype/phenotype correlations in cutaneous severity, susceptibility to atopic dermatitis,[8] growth retardation, skin infection, increased stratum corneum protease activities,[9, 10] and elevated kallikrein levels in the stratum corneum.[11, 12, 13]

Trichorrhexis invaginata, or bamboo hair, is a hair shaft abnormality that occurs as a result of an intermittent keratinizing defect of the hair cortex. Incomplete conversion of the sulfhydryl –SH group onto S-S disulfide bonds in the protein of the cortical fibers leads to cortical softness and subsequent invagination of the fully keratinized distal hair shaft into the softer, abnormally keratinized proximal hair shaft. Intussusception of the distal hair shaft into the proximal hair shaft results in a distinctive ball-and-socket hair shaft deformity. The affected hairs are brittle and breakage is common, resulting in short hairs.

Migratory lesions of ichthyosis linearis circumflexa may be caused by a dermal influx of inflammatory cells that undergo phagocytosis and digestion by keratinocytes, resulting in disruption of keratinization.

Increased transepidermal water loss resulting from the disturbance of corneocyte barrier function in erythroderma may cause profound metabolic abnormalities and hypernatremia,[14, 15] particularly in neonates.[16]

Etiology

Netherton syndrome is a rare autosomal recessive genodermatosis.

Genetics

By linkage analysis and homozygosity mapping in 20 families with Netherton syndrome, Chavanas et al[17] mapped the disease locus to 5q32, which is telomeric to the cytokine gene cluster in 5q31. The SPINK5 gene was mapped to the same region of 5q and, for functional reasons, was considered a candidate gene for Netherton syndrome.[18] Mutations in the SPINK5 gene in 13 families with Netherton syndrome were later reported.[19]

More than 40 distinct SPINK5 mutations have been reported to the Human Gene Mutation Database, with nonsense, splicing, and small insertions/deletions comprising the majority of them.

Biochemical features

Chavanas et al[19] studied steady-state levels of the mRNA encoding LEKTI (lymphoepithelial Kazal-type related inhibitor), the gene product of the SPINK5 gene, in cultured epidermal keratinocytes from a healthy control and 5 Netherton syndrome patients. These extracts showed a marked reduction of signal on Northern blot analysis, suggesting nonsense-mediated decay of mutated transcripts, as is frequently observed in recessive disorders.[20]

SPINK5 mutations lead to truncated LEKTI, with each Netherton syndrome patient possessing LEKTI of a different length.[11] The multidomain proteinase inhibitor LEKTI consists of 15 potential serine proteinase inhibitory domains. LEKTI domain 15 was found to be identical to that of other known Kazal-type inhibitors.[21]

Bitoun et al[22] showed that in contrast to normal skin, LEKTI precursors and proteolytic fragments were not detected in differentiated primary keratinocytes from patients with Netherton syndrome. Defective expression of LEKTI in skin sections was a constant feature in affected individuals, demonstrating that loss of LEKTI expression in the epidermis is a diagnostic feature.

Caspase-1 activity of the stratum corneum and serum interleukin 18 are increased in patients with Netherton syndrome.[21]

LEKTI-deficient epidermis leads to unrestricted kallikrein 5 activity, which activates a protease-induced proinflammatory and proallergic pathway: proteinase-activated receptor 2 (PAR2) – mediated expression of pro-Th2 cytokine thymic stromal lymphopoietin.[23]

Genotype/phenotype correlations

Bitoun et al[24] studied 21 families of different geographic origin and identified 18 mutations, of which 13 were novel and 7 (39%) were recurrent. Five mutations, one of which resulted in perinatal lethal disease in 3 families, were associated with certain ethnic groups. Other lethal variants have also been described.[25]

Hachem et al[26] found that serine protease activity and residual LEKTI expression determine a mild, moderate, or severe phenotype in Netherton syndrome. The degree of clinical severity is related to the magnitude of LEKTI activation. Excess LEKTI leads to loss of desmoglein 1 and desmocollin 1, which play a role in both maintaining epidermal integrity and barrier function.

Komatsu et al[27] linked LEKTI domain deficiency with clinical manifestations in Japanese Netherton syndrome patients by testing the hypothesis that the varying lengths of LEKTI (depending what mutation was found in the patient) correlated with protease inhibitory activity.

Several studies, both in vitro and in vivo, have now demonstrated that loss of LEKTI results in unopposed kallikrein-related peptidase activity and the overactivity of a relatively new epidermal proteinase, elastase 2 (ELA2).[28] Kallikrein-related peptidase 5 (KLK 5) initiates the cascade that leads to desmoglein 1 and desmosome degradation, which results in stratum corneum detachment. This begets the classic scaly skin phenotype seen in affected patients. KLK5 also activates KLK7 and ELA2, effectively altering the skin barrier and facilitating microbe penetration and activation of interleukin 1-beta. In many cases, by triggering the protease-activated receptor 2 (PAR-2), it creates a Th2 proinflammatory environment, activating cytokines such as tumor necrosis factor (TNF)alpha.[28] The Th2 environment has not been consistently demonstrated in all cases .[28] However, it is believed that a functional immune defect could contribute to the frequent infections seen in Netherton syndrome.[28]

In 2014, Wang et al generated an in vitro Netherton syndrome model using SPINK5 small interfering RNA segments (siRNA) introduced into normal epidermal keratinocytes in monolayer culture, which recapitulated some of the morphology of skin in patients with the condition. They found that knockdown of kallikreins led to improvement of epidermal architecture, showing that inhibition of serine proteases KLK5 and KLK7 could be therapeutically beneficial.[7]

Mouse model

SPINK5-/- mice exhibit features of Netherton syndrome, including altered desquamation, impaired keratinization, hair malformation, and a skin barrier defect.[29] In this model, LEKTI deficiency leads to abnormal desmosome cleavage in the upper granular layer through desmoglein 1 degradation by stratum corneum tryptic enzyme and stratum corneum chymotryptic enzymelike hyperactivity.

In 2014, Furio et al created a mouse model that effectively recapitulated the phenotype of patients with Netherton syndrome, in addition to the typical immune milieu. The transgenic mice developed scaly exfoliative erythroderma with a detached stratum corneum, growth restriction, and hair abnormalities. Circulating proinflammatory cytokines, including recruitment of Th2 and Th17 cells in skin, were increased. Serum IgE and IgG were also increased.[30]

Epidemiology

Frequency

The frequency of trichorrhexis invaginata (bamboo hair) is not known. Approximately 200 cases of trichorrhexis invaginata (bamboo hair) have been reported in the literature, but the true incidence is not known. The incidence of trichorrhexis invaginata (bamboo hair) may be as high as 1 case in 50,000 population.[31]

Race

Netherton syndrome has been described in persons of all races.

Sex

Most cases of this condition have been reported in girls. 

Age

Children affected by Netherton syndrome present with erythroderma within 1-6 weeks of birth.

Prognosis

Erythroderma and hair abnormality persist. The disease tends to improve as patients age, but the course can be punctuated by intermittent exacerbations. The erythroderma can change to ichthyosis linearis circumflexa periodically.

Skin colonization and cutaneous infections are common. Cutaneous and systemic infections are common and disturbing consequences in almost all patients with Netherton syndrome.

Patient Education

Note the following organizations:

History

Erythroderma

Most children with Netherton syndrome develop congenital erythroderma, which is evident at birth or during the first weeks of life, placing them at risk for thermal and electrolyte imbalances, dehydration, and sepsis, owing to the profoundly altered epidermal barrier.

Some children do not survive the neonatal period.

Pruritus is a near constant feature.

The erythrodermic phenotype may persist in some individuals for life, but it is more commonly replaced by the characteristic atopic appearance.

Failure to thrive

Failure to thrive may be marked in the first year of life and is often accompanied by symptoms of dermopathic enteropathy, which is a vague condition characterized by steatorrhea that occasionally accompanies erythroderma. Jejunal villous atrophy has been demonstrated in some patients with Netherton syndrome.

Delayed growth and bone development may continue until approximately the second year of life, when most children improve. However, the majority of patients remain below the 25th percentile for height (short stature) and weight secondary to malnutrition.

Allergic manifestations

All patients eventually develop food allergy, particularly to peanuts, eggs, and fish. Most have an atopic predisposition, with a strong family history of asthma, eczema, and hay fever.

Physical Examination

The origin of the term ichthyosis comes from the Greek ichthys, meaning scaly. In fact, Netherton syndrome has been classified as an ichthyosiform syndrome given the occurrence of ichthyosis linearis circumflexa. However, in most children, the most common eruption is an eczematous dermatitis, with characteristic periorificial accentuation. In one study, flexural lichenification was found in all 7 patients and 2 patients had verrucous hypertrophy of the axillae, the inguinal folds, and the lower legs. Ectropion and taut facial skin can develop in older patients with severe disease.

Collodial membrane

It is generally accepted that collodion membrane is distinct and unrelated to Netherton syndrome. In fact, one study reports that colloidal membrane never leads to Netherton syndrome.[32] However, Netherton syndrome has been described as a rare outcome of collodion baby, and the accuracy of this association is debated.

Ichthyosis linearis circumflexa

Ichthyosis linearis circumflexa is characterized by polycyclic and serpiginous migratory pink-red plaques with double-edged scale at the margins. It is a hallmark of Netherton syndrome.

Ichthyosis linearis circumflexa usually occurs after age 2 years and is fairly short-lived, lasting from a few weeks (followed by clearance for months) to years.

Ichthyosis linearis circumflexa appears to last longer in adults than in children.

Ichthyosis linearis circumflexa has been reported as an isolated cutaneous finding in the absence of documented Netherton syndrome in very rare cases,[33] largely prior to our understanding of the genetics of the condition. However, in 2015 its presence was reported in two siblings with a SPINK5 mutation, and it was the only clinical manifestation suggestive of Netherton syndrome.[34] It is likely pathognomonic of the condition.

Hair features (trichorrhexis invaginata)

Trichorrhexis invaginata usually develops after age 1 year.

All patients have sparse, abnormal hair. The hair is short, spiky, lusterless, and brittle.  Clinically, these changes are most apparent over pressure areas such as the occipital and temporal scalp.[35]

Scalp hair grows for a few centimeters before breaking. This finding is particularly evident at the areas of friction, especially the occiput and the temples. The eyebrows also have sparse, broken hair. Older patients may lose their eyebrows and eyelashes altogether.

Microscopic evaluation of clinically normal-appearing hairs may reveal defects. Identifying the bamboo node on the hair shaft using simple microscopy is necessary because unaided visual detection is practically impossible. Dermatoscopic evaluation can aid in detection.[36]   Goujon et al described three characteristic dermatoscopic changes, including bamboo hairs, golf-tee hairs, and matchstick hairs, which are short hair shafts with bulging tips, thought to be due to breakage of bamboo hairs.[37]

The relationship with trauma to the severity of hair-shaft defects is probably overemphasized.

The severity is likely defined by the gene penetrance and tends to improve with age, but the course can be punctuated by intermittent exacerbations.

Pili torti is common.

Trichorrhexis nodosa may also occur, but it is not specific for this condition.

Atopic diathesis

Findings include atopic dermatitis, allergic rhinitis, and asthma.

Complications

The following complications are recognized:

Some patients affected by Netherton syndrome have shown cognitive impairment and developmental delay. Impaired cellular immunity may also be a feature of this condition. The development of aminoaciduria has been described.[38]

Rare complications have also been described, including intracranial hemorrhage, hypothyroidism, rickets, pulmonary hypertension, renal vein thrombosis, and acute pancreatitis.[28, 39, 40, 41, 42, 43]

It remains unclear whether patients have an increased susceptibility for skin malignancies such as squamous cell carcinoma.[44] However, the development of squamous cell carcinomas has been reported in at least six patients, including in the vulva and on the penis.[45]

At least one case of dilated cardiomyopathy in a patient with Netherton syndrome, ultimately requiring cardiac transplantation, has been described in the literature. In the setting of resulting immune suppression, the patient went on to develop CD 30+ primary cutaneous T-cell lymphoproliferative disorder.[46]

Laboratory Studies

Blood

Serum immunoglobulin E (IgE) levels can be increased, sometimes exceeding 10,000 IU/mL.[28]

Specific IgE antibodies to environmental and food allergens can be detected.

Hypereosinophilia can be present.

Other minor and inconsistent immunologic abnormalities have been reported; these abnormalities include transient neutrophil function defects, impaired cellular and immune responses, and raised complement levels (C3 and C4).

Light microscopy of the hair

Examine eyebrows or eyelashes for trichorrhexis invaginata, which appears as bamboo nodes when seen under the light microscope.

Trichorrhexis invaginata is the focal cup-and-ball hair-shaft deformity, with the invagination of the distal hair shaft (ball) into the expanded proximal hair shaft (cup) seen on scanning. This finding is described as a “golf tee” and is characteristic.[50]

Trichorrhexis invaginata may be limited to just a few hairs.  Eyebrows and eyelashes may develop trichorrhexis invaginata earlier, and the eyebrows may be the sole site of involvement; therefore, they should be the specimen of choice.[35, 51, 52] Obtain the hair specimen by clipping, because plucking fractures the hair shaft at the node, rendering microscopy difficult.

All patients have other hair-shaft defects (eg, pili torti, weathering).

Scanning electron microscopy

Electron microscopy shows trichorrhexis invaginata in 10-30% of clipped hair after age 2 years.

The hair fractures at the invaginated node, which is the weakest point in the hair shaft. Electron microscopy can be used to identify these proximal halves of invaginate nodes, which show a cuplike appearance from which the ball of the distal hair has fallen out.

Ultrastructural studies have shown a reduced number of tonofilament-keratohyaline structures, desmosomes, and distorted lamellar bodies. The stratum corneum may lose its lamellar structure.[53, 54, 55]

Other Tests

DNA testing of the SPINK5 gene makes several options possible, including prenatal diagnosis, early diagnosis via postnatal testing, and carrier detection in unaffected family members. Mutations can be identified in two thirds to three quarters of patients with clinically suspected Netherton syndrome. Genetic testing can aid in genetic counseling. Testing is available through the following organizations[56] :

Procedures

Skin biopsy of the skin abnormality may be performed.

Histologic Findings

The histologic features of Netherton syndrome are not diagnostic and vary according to the type of the lesion and when the biopsy sample was obtained. Features of nonspecific dermatitis and psoriasiform hyperplasia are the most common histologic features. Hyperkeratosis is mild in comparison with other ichthyoses. Parakeratosis and an absent granular layer may occur at the spreading edge in ichthyosis linearis circumflexa. A mixed inflammatory cell infiltrate is seen in a perivascular distribution. Arico et al[57] reported increased numbers of CD1 cells similar to atopic dermatitis but also showed raised CD8 positivity rather than CD4 positivity in the dermis, unlike atopic dermatitis. Eosinophilic material (probably a glycoprotein) may accumulate within the granular or parakeratotic horny layer in ichthyosis linearis circumflexa lesions.

Similar to other severe congenital dermatoses, inflammatory changes are common in skin biopsy samples, but whether they are a primary or a secondary phenomenon is not known.

Medical Care

Management is conservative. Emollients, keratolytics, and antibiotics are the mainstay of treatment in Netherton syndrome. White, soft paraffin and liquid paraffin in a ratio of 50:50 have been used as a topical treatment.

Management essentially relies on the treatment of cutaneous infections and other complications.

Topical steroids of moderate potency may be helpful, but reports have described complications such as aminoaciduria and pituitary adrenal axis suppression, especially in patients with widespread erythroderma, and thus should be used with caution.

In one case, split body treatment with 12% lactic acid lotion surprisingly cleared the eruption on the treated side (control side emollient).[58]

Although topical tacrolimus or pimecrolimus was previously discouraged in the treatment of Netherton syndrome due to toxicity from absorption of the medication,[59] newer evidence suggests that pimecrolimus 1% cream applied twice daily may be well tolerated and lead to improvement of skin involvement, with low, safe levels absorbed systemically.[60] Further, larger studies are necessary to elucidate the safety and efficacy of pimecrolimus in Netherton syndrome patients.[60]

Psoralen plus ultraviolet light A (PUVA) and narrowband ultraviolet light B (NBUVB) have been shown to be beneficial in some case reports,[61, 62, 63] though patients treated with these modalities need to be monitored for the development of skin malignancy.[64]

Retinoids are generally not helpful,[65] although a few reports of improvement with a low dose have been published.[66, 67]

Infliximab was found to lead to sustained clinical improvement and clearance of ichthyosis linearis circumflexa in one study.[68]

The potential of treating Netherton syndrome patients with gene therapy[69, 70] and epidermal stem cell therapy[71] is currently being investigated.

A patient allergic to antibiotics showed significant improvement after treatment with several antistaphylococcal bacteriophage preparations.[72]

Consultations

Consult a pediatrician for systemic infections, hypernatremic dehydration, and failure to thrive.

Consult a gastroenterologist for failure to thrive, diarrhea, and villous atrophy of the small bowel.

Consult a geneticist for genetic studies and counseling.

Consider consultation for pelvic examination for men and women with this condition.

Long-Term Monitoring

Trichorrhexis invaginata and ichthyosis linearis circumflexa usually develop after age 2 years, but hair should be examined every 6 months because it rarely may occur earlier.

Author

Laura F McGevna, MD, Assistant Professor of Medicine, Dermatology Division, University of Vermont College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

James W Patterson, MD, Professor of Pathology and Dermatology, Director of Dermatopathology, University of Virginia Medical Center

Disclosure: Nothing to disclose.

Tina S Chen Twu, MD, Pediatric Dermatologist/Dermatologist, Sharp Rees-Stealy Medical Group, San Diego, CA

Disclosure: Nothing to disclose.

Acknowledgements

The author and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Mohsin Ali, MBBS, FRCP, MRCP, and David T Robles, MD, PhD, to the development and writing of this article.

References

  1. Ali M, Marks R, Young E, et al. Netherton's syndrome. A familial occurrence. Br J Dermatol. 1998. 226-271.
  2. Comel M. Ichthyosis linearis circumflexa. Dermatologia. 1949.
  3. Fruhwald R. Zur frage der comelschen krankheit. Dermatol Wochenschr. 1949. 150:289.
  4. Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs. AMA Arch Derm. 1958 Oct. 78(4):483-7. [View Abstract]
  5. Wilkinson RD, Curtis GH, Hawk WA. Netherton's disease: Trichorhexis invafinata (bamboo hair), congenital ichthyosiform erythroderma and atopic diathesis; a histopatholgic study. Arch Dermatol. 1964 Jan. 89:46-54. [View Abstract]
  6. Mevorah B, Frenk E, Brooke EM. Ichthyosis linearis circumflexa comel. A clinico-statistical approach to its relationship with Netherton's syndrome. Dermatologica. 1974. 149(4):201-9. [View Abstract]
  7. Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7. Exp Dermatol. 2014 Jul. 23 (7):524-6. [View Abstract]
  8. Namkung JH, Lee JE, Kim E, Byun JY, Kim S, Shin ES, et al. Hint for association of single nucleotide polymorphisms and haplotype in SPINK5 gene with atopic dermatitis in Koreans. Exp Dermatol. 2010 Dec. 19(12):1048-53. [View Abstract]
  9. Bonnart C, Deraison C, Lacroix M, Uchida Y, Besson C, Robin A, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest. 2010 Mar 1. 120(3):871-82. [View Abstract]
  10. Sales KU, Masedunskas A, Bey AL, Rasmussen AL, Weigert R, List K, et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet. 2010 Aug. 42(8):676-83. [View Abstract]
  11. Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol. 2008 May. 128(5):1148-59. [View Abstract]
  12. Singh G, Miteva M. Prognosis and Management of Congenital Hair Shaft Disorders without Fragility-Part II. Pediatr Dermatol. 2016 Sep. 33 (5):481-7. [View Abstract]
  13. Singh G, Miteva M. Prognosis and Management of Congenital Hair Shaft Disorders with Fragility-Part I. Pediatr Dermatol. 2016 Sep. 33 (5):473-80. [View Abstract]
  14. Jones SK, Thomason LM, Surbrugg SK, Weston WL. Neonatal hypernatraemia in two siblings with Netherton's syndrome. Br J Dermatol. 1986 Jun. 114(6):741-3. [View Abstract]
  15. Stoll C, Alembik Y, Tchomakov D, et al. Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet Couns. 2001. 12(3):237-43. [View Abstract]
  16. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol. 1996 May-Jun. 13(3):183-99. [View Abstract]
  17. Chavanas S, Garner C, Bodemer C, et al. Localization of the Netherton syndrome gene to chromosome 5q32, by linkage analysis and homozygosity mapping. Am J Hum Genet. 2000 Mar. 66(3):914-21. [View Abstract]
  18. Magert HJ, Standker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem. 1999 Jul 30. 274(31):21499-502. [View Abstract]
  19. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000 Jun. 25(2):141-2. [View Abstract]
  20. Culbertson MR. RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet. 1999 Feb. 15(2):74-80. [View Abstract]
  21. Hosomi N, Fukai K, Nakanishi T, Funaki S, Ishii M. Caspase-1 activity of stratum corneum and serum interleukin-18 level are increased in patients with Netherton syndrome. Br J Dermatol. 2008 Sep. 159(3):744-6. [View Abstract]
  22. Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet. 2003 Oct 1. 12(19):2417-30. [View Abstract]
  23. Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol. 2010 Dec. 130(12):2736-42. [View Abstract]
  24. Bitoun E, Chavanas S, Irvine AD, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol. 2002 Feb. 118(2):352-61. [View Abstract]
  25. Capri Y, Vanlieferinghen P, Boeuf B, Dechelotte P, Hovnanian A, Lecomte B. [A lethal variant of Netherton syndrome in a large inbred family]. Arch Pediatr. 2011 Mar. 18(3):294-8. [View Abstract]
  26. Hachem JP, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol. 2006 Jul. 126(7):1609-21. [View Abstract]
  27. Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol. 2008 May. 128(5):1148-59. [View Abstract]
  28. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013 Feb. 351 (2):289-300. [View Abstract]
  29. Descargues P, Deraison C, Bonnart C, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet. 2005 Jan. 37(1):56-65. [View Abstract]
  30. Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med. 2014 Mar 10. 211 (3):499-513. [View Abstract]
  31. Traupe H. The Ichthyoses. A Guide to Clinical Diagnosis, Genetic Counseling, and Therapy. Spirnger Verlag. 1989.
  32. Larregue M, Guillet G. [Collodion baby with neonatal signs of trichothiodystrophy misdiagnosed as Netherton syndrome: reassessment of a previous diagnostic error]. Ann Dermatol Venereol. 2007 Mar. 134(3 Pt 1):245-8. [View Abstract]
  33. Nabai H, Mehregan AH. Ichthyosis linearis circumflexa. J Cutan Pathol. 1979 Apr. 6 (2):148-9. [View Abstract]
  34. Guerra L, Fortugno P, Pedicelli C, Mazzanti C, Proto V, Zambruno G, et al. Ichthyosis Linearis Circumflexa as the Only Clinical Manifestation of Netherton Syndrome. Acta Derm Venereol. 2015 Jun 24. 95 (6):720-4. [View Abstract]
  35. Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. J Am Acad Dermatol. 2014 Sep. 71 (3):415.e1-415.e15. [View Abstract]
  36. Neri I, Balestri R, Starace M, Bardazzi F, Patrizi A. Videodermoscopy of eyelashes in Netherton syndrome. J Eur Acad Dermatol Venereol. 2010 Nov 25. [View Abstract]
  37. Goujon E, Beer F, Fraitag S, Hovnanian A, Vabres P. Matchstick' eyebrow hairs: a dermoscopic clue to the diagnosis of Netherton syndrome. J Eur Acad Dermatol Venereol. 2010 Jun. 24(6):740-1. [View Abstract]
  38. DiGiovanna JJ. Ichthyosiform dermatoses: so many discoveries, so little progress. J Am Acad Dermatol. 2004 Jul. 51 (1 Suppl):S31-4. [View Abstract]
  39. Chao SC, Richard G, Lee JY. Netherton syndrome: report of two Taiwanese siblings with staphylococcal scalded skin syndrome and mutation of SPINK5. Br J Dermatol. 2005 Jan. 152 (1):159-65. [View Abstract]
  40. Garty BZ, Nimri R. Hypothyroidism in Netherton syndrome. Pediatr Dermatol. 2008 Jan-Feb. 25 (1):134-5. [View Abstract]
  41. Söreide K, Söiland H, Körner H, Haga H, Söreide JA. Acute pancreatitis in a young girl with the Netherton syndrome. J Pediatr Surg. 2005 Nov. 40 (11):e69-72. [View Abstract]
  42. Pohl M, Zimmerhackl LB, Hausser I, Ludwig H, Hildebrandt F, Gordjani N, et al. Acute bilateral renal vein thrombosis complicating Netherton syndrome. Eur J Pediatr. 1998 Feb. 157 (2):157-60. [View Abstract]
  43. Macknet CA, Morkos A, Job L, Garberoglio MC, Clark RD, Macknet KD Jr, et al. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation. Pediatr Dermatol. 2008 May-Jun. 25 (3):368-72. [View Abstract]
  44. Natsuga K, Akiyama M, Shimizu H. Malignant skin tumours in patients with inherited ichthyosis. Br J Dermatol. 2011 Aug. 165(2):263-8. [View Abstract]
  45. Isharwal S, Manivel JC, Konety B. Penile cancer in a man with netherton syndrome. Urology. 2015 Apr. 85 (4):e21-2. [View Abstract]
  46. Katugampola RP, Finlay AY, Harper JI, Dojcinov S, Maughan TS. Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome. Br J Dermatol. 2005 Nov. 153 (5):1041-6. [View Abstract]
  47. Goodyear HM, Harper JI. Leiner's disease associated with metabolic acidosis. Clin Exp Dermatol. 1989 Sep. 14(5):364-6. [View Abstract]
  48. Altman J, Stroud J. Neterton's syndrome and ichthyosis linearis circumflexa. Arch Dermatol. 1969 Nov. 100(5):550-8. [View Abstract]
  49. Pichard DC, Freeman AF, Cowen EW. Primary immunodeficiency update: Part I. Syndromes associated with eczematous dermatitis. J Am Acad Dermatol. 2015 Sep. 73 (3):355-64; quiz 365-6. [View Abstract]
  50. de Berker DA, Paige DG, Ferguson DJ, Dawber RP. Golf tee hairs in Netherton disease. Pediatr Dermatol. 1995 Mar. 12(1):7-11. [View Abstract]
  51. Powell J. Increasing the likelihood of early diagnosis of Netherton syndrome by simple examination of eyebrow hairs. Arch Dermatol. 2000 Mar. 136(3):423-4. [View Abstract]
  52. Powell J. Increasing the likelihood of early diagnosis of Netherton syndrome by simple examination of eyebrow hairs. Arch Dermatol. 2000 Mar. 136(3):423-4. [View Abstract]
  53. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol. 1999 Jul. 135(7):823-32. [View Abstract]
  54. Frenk E, Mevorah B. Ichthyosis linearis circumflexa Comèl with Trichorrhexis invaginata (Netherton's Syndrom): an ultrastructural study of the skin changes. Arch Dermatol Forsch. 1972. 245(1):42-9. [View Abstract]
  55. Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol. 2002 Mar. 118(3):436-43. [View Abstract]
  56. Prado R, Ellis LZ, Gamble R, Funk T, Arbuckle HA, Bruckner AL. Collodion baby: an update with a focus on practical management. J Am Acad Dermatol. 2012 Dec. 67 (6):1362-74. [View Abstract]
  57. Arico M, Leonardo S, Pravata G, et al. Netherton's syndrome in male. An immunohistochemical study. Pediatr Dermatol. 1996. 13:183-99.
  58. Wehr RF, Hickman J, Krochmal L. Effective treatment of Netherton's syndrome with 12% lactate lotion. J Am Acad Dermatol. 1988 Jul. 19(1 Pt 1):140-2. [View Abstract]
  59. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001 Jun. 137(6):747-50. [View Abstract]
  60. Yan AC, Honig PJ, Ming ME, Weber J, Shah KN. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch Dermatol. 2010 Jan. 146(1):57-62. [View Abstract]
  61. Nagata T. Netherton's syndrome which responded to photochemotherapy. Dermatologica. 1980. 161(1):51-6. [View Abstract]
  62. Maatouk I, Moutran R, Tomb R. Narrowband ultraviolet B phototherapy associated with improvement in Netherton syndrome. Clin Exp Dermatol. 2012 Jun. 37(4):364-6. [View Abstract]
  63. Kaminska EC, Ortel B, Sharma V, Stein SL. Narrowband UVB phototherapy as a novel treatment for Netherton syndrome. Photodermatol Photoimmunol Photomed. 2012 Jun. 28(3):162-4. [View Abstract]
  64. van der Voort EA, Prens EP. Netherton Syndrome with Multiple Non-melanoma Skin Cancers. Acta Derm Venereol. 2013 Apr 10. [View Abstract]
  65. Hausser I, Anton-Lamprecht I, Hartschuh W, Petzoldt D. Netherton's syndrome: ultrastructure of the active lesion under retinoid therapy. Arch Dermatol Res. 1989. 281(3):165-72. [View Abstract]
  66. Hartschuh W, Hausser I, Petzoldt D. [Successful retinoid therapy of Netherton syndrome]. Hautarzt. 1989 Jul. 40(7):430-3. [View Abstract]
  67. Lazaridou E, Apalla Z, Patsatsi A, Trigoni A, Ioannides D. Netherton's syndrome: successful treatment with isotretinoin. J Eur Acad Dermatol Venereol. 2009 Feb. 23(2):210-2. [View Abstract]
  68. Fontao L, Laffitte E, Briot A, Kaya G, Roux-Lombard P, Fraitag S, et al. Infliximab Infusions for Netherton Syndrome: Sustained Clinical Improvement Correlates with a Reduction of Thymic Stromal Lymphopoietin Levels in the Skin. J Invest Dermatol. 2011 Jun 9. [View Abstract]
  69. Di WL, Larcher F, Semenova E, Talbot GE, Harper JI, Del Rio M, et al. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol Ther. 2011 Feb. 19(2):408-16. [View Abstract]
  70. Roedl D, Oji V, Buters JT, Behrendt H, Braun-Falco M. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients. J Dermatol Sci. 2011 Mar. 61(3):194-8. [View Abstract]
  71. Draheim KM, Lyle S. Epithelial stem cells. Methods Mol Biol. 2011. 750:261-74. [View Abstract]
  72. Zhvania P, Hoyle NS, Nadareishvili L, Nizharadze D, Kutateladze M. Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome. Front Med (Lausanne). 2017. 4:94. [View Abstract]